Abiopharma

New Form SCHEDULE 13G - Roivant Sciences Ltd. Filed: 2025-08-07 AccNo: 0000895421-25-000492 Size: 12 KB

NASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

New Form 144 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Filed: 2025-08-07 AccNo: 0001969223-25-000572 Size: 5 KB

NASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

NASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

New Form S-8 - Trinseo PLC Filed: 2025-08-07 AccNo: 0001558370-25-010736 Size: 443 KB

New Form SCHEDULE 13G/A - Forte Biosciences, Inc. Filed: 2025-08-07 AccNo: 0001549230-25-000022 Size: 15 KB

New Form SCHEDULE 13G - BrightSpring Health Services, Inc. Filed: 2025-08-07 AccNo: 0000914208-25-000267 Size: 13 KB

New Form 6-K - Haleon plc Filed: 2025-08-07 AccNo: 0001654954-25-009201 Size: 114 KB

New Form SCHEDULE 13G/A - Mallinckrodt plc Filed: 2025-08-07 AccNo: 0001393825-25-000034 Size: 10 KB

New Form 4 - FULLER H B CO Filed: 2025-08-07 AccNo: 0001225208-25-007125 Size: 26 KB

Rosen Law Firm Urges Altimmune, Inc. (NASDAQ: ALT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

New Form 6-K - SMITH & NEPHEW PLC Filed: 2025-08-07 AccNo: 0001654954-25-009187 Size: 268 KB

Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

New Form SCHEDULE 13G/A - C4 Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0000895421-25-000489 Size: 7 KB